New pain pill LTG-321 enters first human safety tests
NCT ID NCT07110610
First seen Jun 25, 2026 · Last updated Jun 30, 2026 · Updated 3 times
Summary
This early-stage study tests an experimental oral drug called LTG-321 in 236 healthy adults aged 18-55. The main goal is to check safety and how the body processes the drug. Researchers will also measure pain tolerance using a cold water test and see if a high-fat meal affects drug levels. This is a first step to see if LTG-321 is safe enough for future pain studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LTG-321 (oral drug)
- What this could lead to
- If successful, this could pave the way for further studies of LTG-321 as a potential pain treatment.
- What could go wrong
- This is a very early Phase 1 trial in healthy people, not patients. It primarily tests safety, not effectiveness. The drug may not work or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
New Zealand Clinical Research
Christchurch, New Zealand
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common antifungal change how an experimental drug acts?
- Can a new injection help tackle obesity? a safety trial begins
- Will a new pill formula absorb the same? a trial puts it to the test
- Can a new drug tame Alzheimer's? early trial aims to find out
- Could sitting too much alter your nervous system?
- Could a cancer drug alter Metformin's effects? a trial investigates